Cargando…
Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models
[Image: see text] The ability to cross the blood-brain barrier (BBB) is critical for targeted therapy of the central nerve system (CNS). Six peptide vectors were covalently attached to a 50 kDa poly(β-l-malic acid)-trileucine polymer forming P/LLL(40%)/vector conjugates. The vectors were Angiopep-2...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413444/ https://www.ncbi.nlm.nih.gov/pubmed/35961653 http://dx.doi.org/10.1021/acsnano.1c10034 |
_version_ | 1784775753622093824 |
---|---|
author | Israel, Liron L. Galstyan, Anna Cox, Alysia Shatalova, Ekaterina S. Sun, Tao Rashid, Mohammad-Harun Grodzinski, Zachary Chiechi, Antonella Fuchs, Dieu-Trang Patil, Rameshwar Koronyo-Hamaoui, Maya Black, Keith L. Ljubimova, Julia Y. Holler, Eggehard |
author_facet | Israel, Liron L. Galstyan, Anna Cox, Alysia Shatalova, Ekaterina S. Sun, Tao Rashid, Mohammad-Harun Grodzinski, Zachary Chiechi, Antonella Fuchs, Dieu-Trang Patil, Rameshwar Koronyo-Hamaoui, Maya Black, Keith L. Ljubimova, Julia Y. Holler, Eggehard |
author_sort | Israel, Liron L. |
collection | PubMed |
description | [Image: see text] The ability to cross the blood-brain barrier (BBB) is critical for targeted therapy of the central nerve system (CNS). Six peptide vectors were covalently attached to a 50 kDa poly(β-l-malic acid)-trileucine polymer forming P/LLL(40%)/vector conjugates. The vectors were Angiopep-2 (AP2), B6, Miniap-4 (M4), and d-configurated peptides D1, D3, and ACI-89, with specificity for transcytosis receptors low-density lipoprotein receptor-related protein-1 (LRP-1), transferrin receptor (TfR), bee venom-derived ion channel, and Aβ/LRP-1 related transcytosis complex, respectively. The BBB-permeation efficacies were substantially increased (“boosted”) in vector conjugates of P/LLL(40%). We have found that the copolymer group binds at the endothelial membrane and, by an allosterically membrane rearrangement, exposes the sites for vector–receptor complex formation. The specificity of vectors is indicated by competition experiments with nonconjugated vectors. P/LLL(40%) does not function as an inhibitor, suggesting that the copolymer binding site is eliminated after binding of the vector-nanoconjugate. The two-step mechanism, binding to endothelial membrane and allosteric exposure of transcytosis receptors, is supposed to be an integral feature of nanoconjugate-transcytosis pathways. In vivo brain delivery signatures of the nanoconjugates were recapitulated in mouse brains of normal, tumor (glioblastoma), and Alzheimer’s disease (AD) models. BBB permeation of the tumor was most efficient, followed by normal and then AD-like brain. In tumor-bearing and normal brains, AP2 was the top performing vector; however, in AD models, D3 and D1 peptides were superior ones. The TfR vector B6 was equally efficient in normal and AD-model brains. Cross-permeation efficacies are manifested through modulated vector coligation and dosage escalation such as supra-linear dose dependence and crossover transcytosis activities. |
format | Online Article Text |
id | pubmed-9413444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94134442022-08-27 Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models Israel, Liron L. Galstyan, Anna Cox, Alysia Shatalova, Ekaterina S. Sun, Tao Rashid, Mohammad-Harun Grodzinski, Zachary Chiechi, Antonella Fuchs, Dieu-Trang Patil, Rameshwar Koronyo-Hamaoui, Maya Black, Keith L. Ljubimova, Julia Y. Holler, Eggehard ACS Nano [Image: see text] The ability to cross the blood-brain barrier (BBB) is critical for targeted therapy of the central nerve system (CNS). Six peptide vectors were covalently attached to a 50 kDa poly(β-l-malic acid)-trileucine polymer forming P/LLL(40%)/vector conjugates. The vectors were Angiopep-2 (AP2), B6, Miniap-4 (M4), and d-configurated peptides D1, D3, and ACI-89, with specificity for transcytosis receptors low-density lipoprotein receptor-related protein-1 (LRP-1), transferrin receptor (TfR), bee venom-derived ion channel, and Aβ/LRP-1 related transcytosis complex, respectively. The BBB-permeation efficacies were substantially increased (“boosted”) in vector conjugates of P/LLL(40%). We have found that the copolymer group binds at the endothelial membrane and, by an allosterically membrane rearrangement, exposes the sites for vector–receptor complex formation. The specificity of vectors is indicated by competition experiments with nonconjugated vectors. P/LLL(40%) does not function as an inhibitor, suggesting that the copolymer binding site is eliminated after binding of the vector-nanoconjugate. The two-step mechanism, binding to endothelial membrane and allosteric exposure of transcytosis receptors, is supposed to be an integral feature of nanoconjugate-transcytosis pathways. In vivo brain delivery signatures of the nanoconjugates were recapitulated in mouse brains of normal, tumor (glioblastoma), and Alzheimer’s disease (AD) models. BBB permeation of the tumor was most efficient, followed by normal and then AD-like brain. In tumor-bearing and normal brains, AP2 was the top performing vector; however, in AD models, D3 and D1 peptides were superior ones. The TfR vector B6 was equally efficient in normal and AD-model brains. Cross-permeation efficacies are manifested through modulated vector coligation and dosage escalation such as supra-linear dose dependence and crossover transcytosis activities. American Chemical Society 2022-08-12 2022-08-23 /pmc/articles/PMC9413444/ /pubmed/35961653 http://dx.doi.org/10.1021/acsnano.1c10034 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Israel, Liron L. Galstyan, Anna Cox, Alysia Shatalova, Ekaterina S. Sun, Tao Rashid, Mohammad-Harun Grodzinski, Zachary Chiechi, Antonella Fuchs, Dieu-Trang Patil, Rameshwar Koronyo-Hamaoui, Maya Black, Keith L. Ljubimova, Julia Y. Holler, Eggehard Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models |
title | Signature
Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across
Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse
Models |
title_full | Signature
Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across
Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse
Models |
title_fullStr | Signature
Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across
Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse
Models |
title_full_unstemmed | Signature
Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across
Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse
Models |
title_short | Signature
Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across
Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse
Models |
title_sort | signature
effects of vector-guided systemic nano bioconjugate delivery across
blood-brain barrier of normal, alzheimer’s, and tumor mouse
models |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413444/ https://www.ncbi.nlm.nih.gov/pubmed/35961653 http://dx.doi.org/10.1021/acsnano.1c10034 |
work_keys_str_mv | AT israellironl signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT galstyananna signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT coxalysia signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT shatalovaekaterinas signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT suntao signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT rashidmohammadharun signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT grodzinskizachary signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT chiechiantonella signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT fuchsdieutrang signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT patilrameshwar signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT koronyohamaouimaya signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT blackkeithl signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT ljubimovajuliay signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels AT hollereggehard signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels |